Topics:
Melanoma/Skin Cancer • Medical Oncology
What immunotherapy backbone do you utilize for patients with resectable Stage III melanoma when you offer neoadjuvant therapy?
Do you prefer single agent PD-1 inhibitor or combination immunotherapy?
Answer from: Medical Oncologist at Academic Institution
This is one of the most debated questions in the melanoma community. We personally prefer using single agent anti-PD1 in the neoadjuvant setting based on the results of the SWOG-1801 study. The recently presented data at ESMO 2023 showed a 97% 2-year RFS in patients with complete pathologic response...
Sign in or Register to read more